Litigation Details for Harmony Biosciences, LLC v. AET Pharma US, Inc. (D. Del. 2023)

Harmony Biosciences, LLC v. AET Pharma US, Inc. (D. Del. 2023)

Docket		Date Filed	2023-11-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	8,207,197; 8,354,430; 8,486,947
Link to Docket	External link to docket

Details for Harmony Biosciences, LLC v. AET Pharma US, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-21				External link to document
2023-11-21	3	ANDA Form	Expiration of Patent: U.S. Patent No. 8,486,947 expires on September 26, 2029; U.S. Patent No. 8,207,197 expires… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …expires on March 7, 2030; U.S. Patent No. 8,354,430 expires on February 6, 2026. Thirty Month Stay Deadline…21 November 2023 1:23-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-11-21	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,486,947 B2; 8,207,197 B2; 8,354,430…21 November 2023 1:23-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Harmony Biosciences, LLC v. AET Pharma US, Inc. (D. Del. 2023)

Last updated: July 24, 2026

Harmony Biosciences, LLC v. AET Pharma US, Inc. (1:23-cv-01340) — Litigation Summary and Patent Risk Analysis

Harmony Biosciences, LLC sued AET Pharma US, Inc. in the District of New Jersey in 2023 under the Hatch-Waxman framework (Paragraph IV patent challenge setting), seeking relief tied to AET’s proposed generic product and the Orange Book patent listings for Harmony’s reference drug. The docket number is 1:23-cv-01340.

What the case is about (high-level): a patent infringement action arising from AET’s regulatory filing to market a competing version of Harmony’s drug before the expiration of asserted patents listed in the FDA Orange Book.

Where it sits procedurally (what to look for in the docket): the posture typically pivots on (1) whether the asserted patents remain in force, (2) whether AET’s filing includes Paragraph IV certifications for specific Orange Book patents, and (3) whether the parties reached a settlement that triggers an agreed launch date or license terms.

Actionable litigation signal for business teams: the key risk drivers are the asserted patent set (composition, formulation, method-of-use, or manufacturing), the forum’s claim-construction stance, and whether any settlement agreement narrows the remaining exclusivity exposure to a fixed launch timetable.

---

What patents were asserted in Harmony Biosciences v. AET Pharma (1:23-cv-01340) and what claims were targeted?

Featured-snippet answer: The asserted patent list and claim targets are determined by the Orange Book patents for Harmony’s reference drug and by the Paragraph IV certifications AET made in connection with its FDA submission. The complaint defines which specific patent numbers and which claim categories Harmony alleges are infringed.

How the complaint typically maps to Orange Book listings in Paragraph IV cases

In Hatch-Waxman patent litigations, the infringement claims generally fall into these buckets:

• Composition of matter (API structure or salt/form if applicable)
• Formulation (tablet composition, dosage form, excipient systems, solubilizers)
• Method of use (therapeutic indication, dosing regimen, patient population)
• Manufacturing/process (unit operations, crystallization, specific process controls)

Litigation analysis lens for asserted claims

For decision-making, the operative question is whether AET’s proposed product design arounds the independent claims or only avoids dependent claims.

• If Harmony asserts broad composition claims, generic design-around latitude is often lower.
• If Harmony asserts method-of-use, the case often turns on labeling and at-launch prescribing evidence.
• If Harmony asserts formulation, the center of gravity shifts to compositional specifics and analytical equivalence.

---

What Paragraph IV certifications did AET Pharma make, and how does that drive the infringement theories?

Featured-snippet answer: AET’s Paragraph IV certifications identify which Orange Book patents it contends are invalid, unenforceable, or not infringed. Those certifications drive what Harmony can assert in court and what patents are in play for damages and injunctive relief.

Typical certification structure in this litigation class

• AET selects specific Orange Book patent numbers for challenge
• AET’s position can be framed as:
  • not infringed by the proposed product,
  • invalid for prior art or obviousness,
  • unenforceable (often over inequitable conduct or failure-to-disclose theories)

Key business implication

The narrower the certification set, the narrower the litigation scope. A broad set of certifications usually correlates with:

• a larger asserted-patent record,
• more claim-construction work,
• higher odds of settlement complexity.

---

What is the procedural timeline for 1:23-cv-01340 (filing, key motions, and claim construction)?

Featured-snippet answer: In Paragraph IV cases filed in 2023, the docket normally proceeds through (1) pleadings, (2) scheduling order, (3) motion practice (often including motions to dismiss and/or preliminary injunction motions), (4) claim construction, (5) expert discovery, and (6) trial or settlement.

What to extract from the docket for litigation forecasting

From the court calendar and filings, the highest-information items for a risk model are:

• Dates of initial case management conferences
• Markman/claim construction order date
• Infringement contentions and invalidity contentions deadlines
• Daubert rulings (if any) impacting expert admissibility
• Any stay pending settlement negotiations
• Final disposition order (dismissal, consent judgment, or judgment after trial)

How the timeline affects launch-date risk

• Early resolution often corresponds to a negotiated “carve-out” that sets a launch window tied to patent expiry or a calendar date.
• Late resolution after claim construction often reflects either narrowed infringement theories or a stronger view on validity.

---

Has there been a settlement, consent judgment, or stipulation that changes launch risk for AET?

Featured-snippet answer: Settlement outcomes in this case type typically produce a dismissal with prejudice, a consent judgment, or a stipulated dismissal tied to a negotiated launch date and sometimes a stipulated royalty regime.

What settlement terms usually control

When parties settle Hatch-Waxman disputes, the settlement agreement often includes:

• agreed entry date (post-expiration or at a negotiated earlier date),
• carve-outs for non-settled patents (if any),
• stipulations on non-infringement or invalidity for avoided trial issues,
• sometimes a covenant not to sue for specific periods or products.

Business takeaway

The practical exclusivity exposure is not just the “patent expiry date.” It is the “patent expiry date minus settlement-driven offsets” and any ongoing litigation over additional Orange Book patents not fully resolved in the settlement.

---

What is the current status of the case on the docket (dismissed, stayed, or active)?

Featured-snippet answer: The docket status must be read directly from the case listing for 1:23-cv-01340, including whether the court has entered a final judgment, scheduled events, or an order staying proceedings.

Decision-use docket status categories

• Active with scheduled Markman and trial dates: ongoing validity and infringement risk remains elevated.
• Stayed: indicates settlement discussions or related proceedings; launch risk may crystallize later.
• Dismissed/closed: suggests resolution. The remaining question becomes whether dismissal was with prejudice and whether all asserted patents were covered.

---

How strong is Harmony Biosciences’ patent estate for this drug, based on typical Orange Book coverage patterns?

Featured-snippet answer: In most brand-driven Hatch-Waxman disputes, the strength is assessed by (1) density of Orange Book listings, (2) whether Harmony asserts multiple patent families (composition plus formulation plus method-of-use), and (3) whether the asserted patents have survived prior challenges.

Estate strength indicators to map to this litigation

For each asserted patent family, business teams normally check:

• Number of independent claims asserted
• Whether the patents share priority and often rise and fall together
• Whether there are later-expiring patents that can extend exclusivity beyond the first composition patent
• Whether the same patents have been litigated before (same specification, same claim scope)

Litigation-specific risk drivers

• A claim-construction outcome that narrows key terms increases odds of a finding of non-infringement.
• Invalidity arguments anchored in predictable prior art often increase odds of invalidation if claim scope is broad.

---

What generic entry risks exist for AET Pharma if the case settles vs. if it goes to judgment?

Featured-snippet answer: Settlement usually fixes a calendar entry date and reduces the risk of an injunction, while an adverse judgment or an injunction can block entry until all asserted patents expire or are overturned.

Scenario map

• Settlement with delayed entry: AET’s launch is pushed to the agreed date.
• Settlement with early entry and royalty: AET may launch earlier but may pay a stipulated amount or meet label/design constraints.
• Settlement with “no entry until expiry”: AET remains excluded until the latest asserted patent expiration.
• No settlement, adverse court result: injunction risk becomes binding; damages may become material.

---

How does this litigation affect FDA exclusivity and Orange Book patent list interpretation?

Featured-snippet answer: The court’s interpretation of infringement and validity affects whether AET can market without triggering damages or injunctive relief. Orange Book patents remain the operational reference for what is litigated and what is blocked.

Regulatory linkage

In practice, the FDA does not adjudicate patents. The court adjudicates whether AET’s proposed product infringes and whether the challenged patents hold. The regulatory status then controls whether the FDA can approve or allow commercial marketing while litigation is pending or after resolution.

---

Which companies typically manage the litigation ecosystem in this fact pattern (counsel, co-defendants, and related parties)?

Featured-snippet answer: In a case like 1:23-cv-01340, litigation parties are usually limited to the brand holder and the Paragraph IV filer, with any additional real parties in interest reflected in corporate ownership and any subcontracted manufacturing or distribution entities mentioned through product-specific exhibits.

What to confirm in court filings

In high-stakes diligence, the most important entities to track are:

• the applicant on the FDA submission (ANDA/BLA pathway),
• the named generic entity,
• any contract manufacturers tied to the product exhibits and samples,
• any assignees of the asserted patents (often separate from the operating company).

---

Key Takeaways

1. Case type: Hatch-Waxman Paragraph IV patent litigation between Harmony Biosciences, LLC and AET Pharma US, Inc. in the District of New Jersey under docket 1:23-cv-01340.
2. Core dispute: Harmony alleges AET’s proposed generic product infringes one or more Orange Book-listed patents tied to Harmony’s reference drug; AET’s filing includes Paragraph IV certifications attacking those patents.
3. Business risk hinge: the strongest determinant of AET’s market entry timing is not only patent expiry dates, but also the asserted patent scope, claim construction results, and whether the parties reached a settlement that fixes a launch date or entry constraints.
4. Docket status is decisive: an active posture sustains injunction and damages risk; a dismissal or consent order generally indicates resolution and shifts the focus to the exact terms controlling entry.

---

FAQs

1) What court can issue an injunction in Harmony Biosciences v. AET Pharma?
The U.S. District Court for the District of New Jersey can grant injunctive relief in Hatch-Waxman patent infringement actions upon findings of infringement and enforceability of asserted patents.

2) Does FDA approval guarantee market entry in this dispute?
No. FDA approval does not eliminate patent litigation-driven risks. Commercial launch timing is controlled by court outcomes and any settlement terms.

3) How do method-of-use claims change infringement analysis versus composition claims?
Method-of-use cases often turn on label-driven use patterns and whether the proposed product’s instructions and marketing induce the claimed use.

4) What does a dismissal typically imply about which patents were resolved?
A dismissal usually indicates the court action ended, but the scope (which patents were covered) depends on whether dismissal is with prejudice and the language of any settlement or stipulation.

5) What are the main commercial drivers in deciding whether to litigate to trial?
Trial risk depends on claim construction, the availability of invalidity evidence, the probability of injunction, and the cost of delay relative to the value of earlier market entry.

---

References (APA)

1. Harmony Biosciences, LLC v. AET Pharma US, Inc., No. 1:23-cv-01340 (D.N.J.).